Skip to content
TBC
lls
  • Home
  • All Episodes
    • CAR T-cell Therapy
    • Leukemia
    • Lymphoma
    • Myelodysplastic Syndromes
    • Myeloma & Amyloidosis
    • Pediatric and AYA
    • General Treatment & Support
  • Subscribe by Email
  • About
  • FAQs
  • Visit LLS.org

Category Archives: CAR T-cell Therapy

CAR T-cell Therapy in 2022: What You Need to Know

Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA

Highpoints from Attending the 2021 American Society of Hematology Conference

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY

CAR T-cell Therapy: The Nurse’s Role in Treating Patients

Elizabeth A. Weber, BSN, RN, Heather DiFilippo, MSN, CRNP and Erin Medoff, RN, MSN, APRN

A Discussion on the Future of CAR T-cell Therapy with Dr. Frederick Locke

Frederick L. Locke, MD, Moffitt Cancer Center, Tampa, FL

CAR T-cell Therapy: A Deeper Dive into Adverse Effects and Financial Toxicities

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center and Gunjan Shah, MD, Memorial Sloan Kettering Cancer Center

CAR T-cell Therapy: A 60,000 Foot View

Dennis Cooper, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Post navigation

« Previous 1 2

Categories

  • All Episodes (103)
  • CAR T-cell Therapy (12)
  • Clinical Trials (4)
  • COVID-19 (7)
  • General Treatment & Support (34)
  • Genomics (3)
  • Health Equity (8)
  • Leukemia (24)
  • Lymphoma (15)
  • Minimal Residual Disease (MRD) (4)
  • Myelodysplastic Syndromes (6)
  • Myeloma & Amyloidosis (14)
  • Myeloproliferative Neoplasms (4)
  • Pediatric and AYA (13)
  • Rare Blood Cancers (4)
  • Transplantation (4)
  • Waldenström macroglobulinemia (2)

Find us on your favorite podcatchers

Apple PodcastsSpotifyAmazon MusicAndroidiHeartRadioJioSaavnPodchaserPodcast Indexby EmailRSSMore Subscribe Options
For a complete listing of continuing education programs, visit www.LLS.org/CE     |      Disclaimer
2024 Treating Blood Cancers Podcast Series – The Leukemia & Lymphoma Society